Bohdan Kysilov

Bohdan Kysilov

Auto-generated profile, based on publicly available information

Bohdan Kysilov

Institute of Physiology CAS

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2021 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
Kristyna MazochováKristyna Mazochová
Kristyna Mazochová
HDHynek Danda
Hynek Danda
WDWim Dehaen
Wim Dehaen
BJBronislav Jurásek
Bronislav Jurásek
KŠKlára Šíchová
Klára Šíchová
TPTomáš Páleníček
Tomáš Páleníček

12 January 2024 in Cellular and Molecular Life Sciences
Verified
Journal Article
Open access
PDF file
BKBohdan Kysilov
Bohdan Kysilov
VKViktor Kuchtiak
Viktor Kuchtiak
BKBarbora Hrcka Krausova
Barbora Hrcka Krausova
ABAles Balik
Ales Balik
MKMiloslav Korinek
Miloslav Korinek
LVLadislav Vyklický
Ladislav Vyklický
N-methyl-d-aspartate receptors (NMDARs) play a critical role in normal brain function, and variants in genes encoding NMDAR subunits have been described in individuals with various neuropsychiatric disorders. We have used whole-cell patch-clamp electrophysiology, fluorescence microscopy and in-silico modeling to explore the functional consequences of disease-associated nonsense and frame-shift variants resulting in the truncation of GluN2A or GluN2B C-terminal domain (CTD). This study characterizes variant NMDARs and shows their reduced surface expression and synaptic localization, altered agonist affinity, increased desensitization, and reduced probability of channel opening. We also show that naturally occurring and synthetic steroids pregnenolone sulfate and epipregnanolone butanoic acid, respectively, enhance NMDAR function in a way that is dependent on the length of the truncated CTD and, further, is steroid-specific, GluN2A/B subunit-specific, and GluN1 splice variant-specific. Adding to the previously described effects of disease-associated NMDAR variants on the receptor biogenesis and function, our results improve the understanding of the molecular consequences of NMDAR CTD truncations and provide an opportunity for the development of new therapeutic neurosteroid-based ligands.

10 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
VAVera Abramova
Vera Abramova
ETEni Tomovic
Eni Tomovic
BKBohdan Kysilov
Bohdan Kysilov
MKMiloslav Korinek
Miloslav Korinek
MDMark Dobrovolski
Mark Dobrovolski
LVLadislav Vyklický
Ladislav Vyklický
N-methyl-D-aspartate receptors (NMDARs) control synaptic plasticity and brain development in a manner determined by receptor subunit composition. Pathogenic variants in GRIN2A gene, encoding the NMDAR GluN2A subunit, can cause gain or loss of function of receptors containing the affected subunit, and are associated with intellectual disability and epilepsy in patients. While in-vitro studies of recombinant receptors have yielded some insights, animal experimental models are essential to better understand the relationship between the molecular pathology of the variants and the disease. Here we introduce a zebrafish model of GluN2A loss of function to study system-level effects of zebrafish grin2Aa and grin2Ab gene deletion. Our electrophysiological analysis revealed functional differences between receptors containing zebrafish GluN2Aa/b and GluN2Bb paralogs comparable to mammalian receptors containing GluN2A vs. GluN2B subunits. Both grin2Aa −/− and grin2Ab −/− , as well as double-knockout grin2A −/− zebrafish larvae showed increased locomotor activity in a novel environment. Proteomic analysis suggested that the relative proportion of GluN2B-containing NMDARs may be increased in grin2A mutant fish. Our results highlight fundamental similarities between zebrafish and mammalian NMDAR signaling and validate the use of zebrafish as a model organism to study the neurodevelopmental role of NMDARs. The newly created transgenic zebrafish strains complement the rodent models of GluN2A loss of function and can be used for high-throughput testing of pharmacological or genetic treatment strategies for patients with GRIN2A gene variants.

3 October 2025 in bioRxiv
Verified
Preprint
Open access
SASantosh Kumar Adla
Santosh Kumar Adla
BKBarbora Hrcka Krausová
Barbora Hrcka Krausová
BKBohdan Kysilov
Bohdan Kysilov
KKKarel Kudláček
Karel Kudláček
RSRadko Souček
Radko Souček
EKEva Kudova
Eva Kudova
N -methyl-D-aspartate receptors (NMDARs) are crucial therapeutic targets, modulated by endogenous neurosteroids like pregnenolone sulfate ( PES ). This study investigates a novel structure-activity relationship approach focusing on the steroidal D-ring, employing the bioisosteric replacement of C-17 or C-20 keto groups with oximes and oxime ethers. We synthesized a series of pregn-5-ene and androst-5-ene derivatives ( 11 – 23 ) and evaluated their positive allosteric modulator (PAM) activity on recombinant rat GluN1/GluN2B receptors via patch-clamp in HEK293 cells. Our study revealed that pregnenolone-derived C-20 oxime ethers are potent and efficacious PAMs of NMDAR. Several analogues have been demonstrated as more potent than PES (E max = 116%; EC 50 = 21.7 µM). Compound 12 (C-20 ethyl oxime ether, C-3 hemiglutarate) displayed the highest efficacy, potentiating NMDAR currents over 6-fold more than PES (E max = 673 ± 121%; EC 50 = 8.7 ± 1.1 µM). Compound 17 (C-20 methyl oxime ether analogue) exhibited the highest potency, being over 3.5-fold more potent than PES (E max = 503 ± 68%; EC 50 = 6.1 ± 0.4 µM). In contrast, some C-17 analogues and derivatives with bulkier C-20 oxime substituents showed complex modulatory behavior. Promisingly, key compounds demonstrated favorable in vitro ADME profiles, including high metabolic stability and, for 12 , excellent thermodynamic solubility. These results validate C-20 oxime ether modification of the pregnenolone scaffold as an effective strategy for generating potent NMDAR PAMs with potentially superior efficacy and drug-like properties compared to endogenous modulators.